Cytokinetics (CYTK) Scheduled to Post Earnings on Thursday

Cytokinetics (NASDAQ:CYTK) will be releasing its earnings data after the market closes on Thursday, February 21st. Analysts expect Cytokinetics to post earnings of ($0.55) per share for the quarter.

NASDAQ:CYTK opened at $7.60 on Thursday. Cytokinetics has a 52-week low of $5.90 and a 52-week high of $10.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 10.58 and a current ratio of 10.57. The firm has a market cap of $409.79 million, a price-to-earnings ratio of -2.93 and a beta of 2.17.

Several research firms have issued reports on CYTK. BidaskClub downgraded Cytokinetics from a “hold” rating to a “sell” rating in a report on Thursday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Cytokinetics in a report on Tuesday, January 22nd. ValuEngine raised Cytokinetics from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. Finally, Zacks Investment Research raised Cytokinetics from a “sell” rating to a “hold” rating and set a $8.00 price objective on the stock in a report on Friday, November 2nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Cytokinetics currently has an average rating of “Buy” and an average target price of $12.79.

In other Cytokinetics news, CEO Robert I. Blum sold 4,000 shares of the company’s stock in a transaction on Friday, January 4th. The stock was sold at an average price of $7.11, for a total transaction of $28,440.00. Following the transaction, the chief executive officer now owns 148,022 shares of the company’s stock, valued at approximately $1,052,436.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 12,500 shares of company stock worth $91,395. Company insiders own 5.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cytokinetics (CYTK) Scheduled to Post Earnings on Thursday” was reported by Modern Readers and is the sole property of of Modern Readers. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Earnings History for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with's FREE daily email newsletter.

Leave a Reply